Logo Text

Our Focus backup

Home » Our Focus backup

Asiapac: The moving Center of Gravity of the Pharma Industry

  • Vast geography home to 3 Billion people
  • Economy of $20 Trillion with China, Japan, India, Australia & Korean among the Top 15 economies
  • Total Pharma market size of $242 Bill in 2011 & expected to be $420 Bill by 2020
  • Healthy growth of 9% in the region and 14% without Japan. Pure generic growth well over 15%
  • APAC will contribute 51% of value growth to world market by 2020
  • Harmonized ACTD regulatory guidelines across ASEAN markets
  • Healthcare reforms/insurance just starting in many markets
focus1

PHILIPPINES: A SNAPSHOT vis-à-vis GLOBAL MARKET

USD 4.4 B 0.4% of global market

Prescription driven products market

Overfocus on pricing

focus2

Essentially an OOP market

Formulation exports is negligible business

Sourcing and import dependent

Taiwan

US$ 4.5 Bill

Reimbursement market driven by hospital’s buying power

Not crowded, longer gestation but attractive margins

focus3
focus4

Vietnam

US$ 2.6 Bill

Growing at 13 %

Market split into volume products and newer products.

focus5

Brazil

  • 8th Largest market in the world
  • Estimated to be US$ 26 .5 Billion
  • 35 % of Latin American market , Growing at 11 %
  • Generic penetration about 23 % and growing at 18 %
  • Out of 540 companies 90 are in generics
  • Top 5 TAs /Opportunities -in Cardio ( Angiotensin II Antagonist & Lipid regulators ), Antiulcerants , Oral Diabetes, Obesity and Muscle relaxants.
  • Initially licensing or contract manufacturing
  • Need investment in ANVISA approval and PE/BEs at approved CROs
  • Prices higher than even many Asian markets

South Africa

  • Total market US$ 4.2 Bill growing at 12 .6 %
  • Privately supplied worth ZAR 19.5 Bill ( 80 % ) & State funded worth ZAR 4.7 Bill ( 20 % )
  • Private market generic penetration is 58 %
  • NHI bill tabled in parliament
  • Process of marketing being reviewed.
  • SAHPRA severely under-resourced with delays of 5 years in approvals
  • Over 75 % imports but still very attractive markets for niche products.
focus6